Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Stockholm
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

KARO:SS

1.4400 SEK 0.00000.00%

As of 11:30:00 ET on 05/22/2015.

Snapshot for Karo Bio AB (KARO)

Open: 1.4500 Day's Range: 1.4200 - 1.4500 Volume: 1,249,648
Previous Close: 1.4400 52wk Range: 0.5550 - 1.9400 1-Yr Rtn: +50.00%

Stock Chart for KARO

No chart data available.
  • KARO:SS 1.4400
  • 1D
  • 1M
  • 1Y
1.4400
Interactive KARO Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for KARO

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. OMX -
Earnings Per Share (SEK) (ttm) -0.0830
Est. EPS (SEK) (12/2015) -
Est. PEG Ratio -
Market Cap (M SEK) 993.23
Shares Outstanding (M) 689.74
30 Day Average Volume 4,141,339
Price/Book (mrq) 15.5349
Price/Sale (ttm) 51.5622
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 07/10/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for KARO

  • Revenue
  • Net Income (M/SEK)
  • Profit Margin (%)

Company Profile & Key Executives for KARO

Karo Bio AB operates a drug research and development company. The Company develops precision drugs to treat major diseases in the field of nuclear receptors. Karo Bio works within many therapeutic areas including men and women's health, cardiovascular diseases, metabolic disorders and dermatology.

Maria SjoebergChief Executive OfficerHenrik PalmExec Vice President
Anneli HallgrenChief Scientific Ofcr/VP:DvptMark FarmeryHead:Business Development
More Company Profile & Key Executives for KARO

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil